Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Stenzl A, Sternberg CN, Ghith J, Serfass L, Schijvenaars BJ, Sboner A. Application of artificial intelligence to overcome clinical information overload in urological cancer. BJU Int. 2022;130(3):291-300.

Kudalkar EM, Pang C, Haag MM, Pollyea DA, Kamdar M, Xu G, et al. 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. Mol Cytogenet. 2022;15(1):30.

Church AJ, Corson LB, Kao P-, Imamovic-Tuco A, Reidy D, Doan D, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022;28(8):1581-1589.

Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, et al. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022;15(1):3-10.

Buyukozkan M, Alvarez-Mulett S, Racanelli AC, Schmidt F, Batra R, Hoffman KL, et al. Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. iScience. 2022;25(7):104612.

McLean-Holden AC, Rooper LM, Lubin DJ, Magliocca KR, Manucha V, Sadow PM, et al. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head Neck Pathol. 2022;16(3):657-669.

Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, et al. Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. NPJ Precis Oncol. 2022;6(1):33.

Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, et al. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022;107(1):201-210.

Haas M, Mirocha J, Amann K, Bajema IM, Barisoni L, Becker JU, et al. Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy. Kidney Int Rep. 2022;7(1):78-86.

Kwon O-, Zhang B, Jia D, Zhang L, Wei X, Zhou Z, et al. Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene. 2022;41(9):1309-1323.